PT2634191E - Processo para preparar derivados de tienopirimidinadiona - Google Patents

Processo para preparar derivados de tienopirimidinadiona Download PDF

Info

Publication number
PT2634191E
PT2634191E PT13002731T PT13002731T PT2634191E PT 2634191 E PT2634191 E PT 2634191E PT 13002731 T PT13002731 T PT 13002731T PT 13002731 T PT13002731 T PT 13002731T PT 2634191 E PT2634191 E PT 2634191E
Authority
PT
Portugal
Prior art keywords
thienopyrimidinedione
preparing derivatives
derivatives
preparing
Prior art date
Application number
PT13002731T
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Nayan Taterao Waghmare
Sanjay Margal
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PT2634191E publication Critical patent/PT2634191E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT13002731T 2009-03-23 2010-03-23 Processo para preparar derivados de tienopirimidinadiona PT2634191E (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2213MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12

Publications (1)

Publication Number Publication Date
PT2634191E true PT2634191E (pt) 2015-03-04

Family

ID=42780205

Family Applications (3)

Application Number Title Priority Date Filing Date
PT107160509T PT2411395E (pt) 2009-03-23 2010-03-22 Derivados de furopirimidinadiona como moduladores de trpa1
PT107517120T PT2411396E (pt) 2009-03-23 2010-03-23 Derivados de tienopirimidinadiona como moduladores de trpa1
PT13002731T PT2634191E (pt) 2009-03-23 2010-03-23 Processo para preparar derivados de tienopirimidinadiona

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT107160509T PT2411395E (pt) 2009-03-23 2010-03-22 Derivados de furopirimidinadiona como moduladores de trpa1
PT107517120T PT2411396E (pt) 2009-03-23 2010-03-23 Derivados de tienopirimidinadiona como moduladores de trpa1

Country Status (23)

Country Link
US (4) US20120178766A1 (pt)
EP (3) EP2411395B1 (pt)
JP (2) JP2012521406A (pt)
KR (2) KR20110128898A (pt)
CN (3) CN102361874A (pt)
AP (1) AP2948A (pt)
AU (2) AU2010227225A1 (pt)
BR (2) BRPI1013705A2 (pt)
CA (2) CA2756535A1 (pt)
DK (3) DK2411395T3 (pt)
EA (2) EA201190138A1 (pt)
ES (3) ES2424341T3 (pt)
HK (2) HK1166074A1 (pt)
HU (1) HUE024538T2 (pt)
IL (2) IL215175A (pt)
MX (1) MX2011009822A (pt)
PE (2) PE20120834A1 (pt)
PL (3) PL2411395T3 (pt)
PT (3) PT2411395E (pt)
SG (4) SG174398A1 (pt)
SI (3) SI2411395T1 (pt)
WO (2) WO2010109329A1 (pt)
ZA (2) ZA201107650B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
EA023857B1 (ru) 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
BR112013032025A2 (pt) * 2011-06-13 2016-12-20 Glenmark Pharmaceutical S A antagonistas trpa1, compostos ou seus sais farmaceuticamente aceitáveis, métodos para reduzir a quantidade de eosinófilos ou neutrófilos e/ou aumentar fev1 em indivíduo com distúrbio respiratório, para tratar distúrbio respiratório em indivíduo e/ou para identificar antagonista trpa1, usos de quantidade eficaz de antagonista trpa1, e composição farmacêutica para administração por inalação
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
JP2014517062A (ja) 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
US20140364445A1 (en) * 2011-12-05 2014-12-11 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
AU2013273118B2 (en) * 2012-06-08 2015-11-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
SG11201502150PA (en) 2012-10-01 2015-04-29 Orion Corp N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists
US10603277B2 (en) * 2013-06-20 2020-03-31 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a TRPA1 antagonist
US9532988B2 (en) 2013-10-15 2017-01-03 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
EP3180337B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
US20190175599A1 (en) * 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
EP3439656A4 (en) * 2016-04-07 2020-03-11 Duke University SMALL MOLECULAR DUAL INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTING AND STUNNING
CN114874209B (zh) * 2017-03-07 2024-08-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6300334B1 (en) * 1998-08-28 2001-10-09 Astrazeneca Ab Thieno[2,3-d]pyrimidine-2,4-diones
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
DE60332475D1 (de) * 2002-10-30 2010-06-17 Vertex Pharma Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical MERGED PYRIMIDINE DERIVATIVE AND USE THEREOF
WO2005077959A1 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
US20090062258A1 (en) 2005-02-03 2009-03-05 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
JP2009503107A (ja) * 2005-08-04 2009-01-29 アポジー・バイオテクノロジー・コーポレイション スフィンゴシンキナーゼ阻害剤およびそれらの使用方法
CN101351463A (zh) * 2005-11-08 2009-01-21 欧加农股份有限公司 用于治疗trpv1相关病症的2-(苯并咪唑-1-基)-n-(4-苯基噻唑-2-基)乙酰胺衍生物
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
TWI649092B (zh) * 2005-12-22 2019-02-01 海卓勒生物科學公司 用於調節ｔｒｐａ１功能之化合物
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
US8163761B2 (en) * 2007-06-22 2012-04-24 Hydra Biosciences, Inc. Methods and compositions for treating disorders
CN101711413B (zh) * 2007-06-25 2013-09-04 桑迪士克科技股份有限公司 具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
KR20120001746A (ko) 2009-03-23 2012-01-04 그렌마크 파머수티칼스 에스. 아. Ｔｒｐａ1 조절자로서 이소티아졸로-피리미딘디온 유도체
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
EP2488524B1 (en) 2009-10-15 2013-07-03 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2786800C (en) 2010-01-12 2018-02-27 Ab Science Thiazole and oxazole kinase inhibitors
SG178311A1 (en) 2010-07-13 2012-03-29 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders

Also Published As

Publication number Publication date
CN103755720B (zh) 2016-07-06
EP2634191B1 (en) 2014-12-24
US20120295924A1 (en) 2012-11-22
ES2424341T3 (es) 2013-10-01
PL2411396T3 (pl) 2013-10-31
CA2756535A1 (en) 2010-09-30
IL215175A0 (en) 2011-12-29
EP2411396B1 (en) 2013-05-29
PE20120775A1 (es) 2012-06-27
KR20120004422A (ko) 2012-01-12
EP2411396A2 (en) 2012-02-01
PE20120834A1 (es) 2012-07-25
ZA201107649B (en) 2012-07-25
BRPI1009381A2 (pt) 2016-06-21
CA2756536C (en) 2015-10-06
PL2411395T3 (pl) 2013-10-31
AU2010227230B2 (en) 2015-11-26
WO2010109329A1 (en) 2010-09-30
EP2634191A1 (en) 2013-09-04
DK2411396T3 (da) 2013-08-05
EA201190138A1 (ru) 2013-05-30
KR20110128898A (ko) 2011-11-30
US9474758B2 (en) 2016-10-25
ES2424342T3 (es) 2013-10-01
IL215177A (en) 2014-01-30
BRPI1013705A2 (pt) 2016-04-05
CN103755720A (zh) 2014-04-30
SI2634191T1 (sl) 2015-04-30
AU2010227225A2 (en) 2011-10-06
SG174398A1 (en) 2011-10-28
SG174404A1 (en) 2011-10-28
SG184769A1 (en) 2012-10-30
AU2010227225A1 (en) 2011-09-15
HK1166074A1 (en) 2012-10-19
US20130289054A1 (en) 2013-10-31
SI2411396T1 (sl) 2013-07-31
WO2010109334A2 (en) 2010-09-30
BRPI1009381B1 (pt) 2020-04-14
PL2634191T3 (pl) 2015-06-30
SI2411395T1 (sl) 2013-07-31
EA201190139A1 (ru) 2012-03-30
WO2010109334A3 (en) 2010-11-25
AP2011005889A0 (en) 2011-10-31
JP2012521407A (ja) 2012-09-13
HUE024538T2 (hu) 2016-01-28
AU2010227230A2 (en) 2011-10-27
AU2010227230A1 (en) 2011-09-22
AP2948A (en) 2014-07-31
DK2634191T3 (en) 2015-03-23
US20120178766A1 (en) 2012-07-12
JP2012521406A (ja) 2012-09-13
PT2411395E (pt) 2013-06-06
EP2411395B1 (en) 2013-05-29
US20150150876A1 (en) 2015-06-04
EA022029B1 (ru) 2015-10-30
ES2532386T3 (es) 2015-03-26
PT2411396E (pt) 2013-06-06
SG184767A1 (en) 2012-10-30
CN102361877A (zh) 2012-02-22
DK2411395T3 (da) 2013-08-05
KR101524337B1 (ko) 2015-05-29
ZA201107650B (en) 2012-07-25
CA2756536A1 (en) 2010-09-30
US8507503B2 (en) 2013-08-13
CN102361877B (zh) 2014-05-07
BRPI1009381B8 (pt) 2021-05-25
HK1166073A1 (en) 2012-10-19
IL215177A0 (en) 2011-12-29
CN102361874A (zh) 2012-02-22
US8987278B2 (en) 2015-03-24
JP5612070B2 (ja) 2014-10-22
EP2411395A1 (en) 2012-02-01
IL215175A (en) 2014-01-30
MX2011009822A (es) 2012-01-25

Similar Documents

Publication Publication Date Title
SI2634191T1 (sl) Postopek za pripravo derivatov tienopirimidindiona
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
IL218101A0 (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
PL2614826T3 (pl) Sposób wytwarzania pochodnych tiazolu
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
ZA201202504B (en) Process for the preparation of calcobutrol
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
IL222290A0 (en) Process for preparing aminobenzofuran derivatives
EP2407461A4 (en) PROCESS FOR PREPARING 1-ALKYL-5-BENZOYL-1H-TETRAZOL DERIVATIVES
IL222191A0 (en) Process for preparing sulfonamido-benzofuran derivatives
IL220211A0 (en) Process for the preparation of 1-alkyl-/1-aryl-5-pyrazolecarboxylic acid derivatives
PL390042A1 (pl) Sposób wytwarzania kwasu chlebowego
IL218140A0 (en) Process for preparing 1-phenylpyrazoles
IL227220A (en) A process for preparing a history of 3-alkylsulfinylbenzoyl
PT2477964E (pt) Processo para a preparação de derivados de alfa-carboxamida
EP2456778A4 (en) PROCESS FOR PRODUCING FLUOROCYTIDINE DERIVATIVES
IL219138A0 (en) Process for the preparation of 4-sulfinyl-pyrazole derivatives
PL388931A1 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
IL214764A0 (en) Process for the preparation of pyrazole derivatives
EP2619174A4 (en) PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES
HUP0900788A2 (en) Process for producing 4-bromomethyl-biphenyl derivatives
EP2423187A4 (en) PROCESS FOR PRODUCING N-ALCOXYCARBONYL-tert-LEUCINS
EP2578568A4 (en) PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED FLUOROPYRROLIDINE DERIVATIVES
HK1171759A1 (zh) 螺酮縮醇衍生物的製備方法
IL226097A0 (en) A process for the production of derivatives of 4-carbonyloxyquinoline